# Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

> **NCT02566772** · PHASE1 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 130 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** TAS3681

## Key facts

- **NCT ID:** NCT02566772
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2022-08-09
- **Final completion:** 2024-04-26
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566772, "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02566772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*